Novel in situ gelling is gaining ground
Ophthalmic drug delivery is the most challenging delivery amongst all delivery routes. Global as well as Indian market... more Ophthalmic drug delivery is the most challenging delivery amongst all delivery routes. Global as well as Indian market of ocular systems is of large size due high prevalence of ocular diseases. Novel in situ gelling systems are of great importance nowadays with combined advantage of patient compliance and reduced systemic side effects. Temperature, ionic strength and pH changes induce formation of in situ gels. Current article provides overview of global market for ophthalmics, preparation methods, polymers used and evaluation methods for the in situ gels.
Trends in dissolution enhancement technologies
Most of the newly invented drugs are of high molecular weights and hence have high lipophilic nature. Due to this,... more Most of the newly invented drugs are of high molecular weights and hence have high lipophilic nature. Due to this, solubility in body fluids is major concern. Low solubility of drugs causes low bioavailability, increased change of food effect and incomplete release. Dissolution testing acts as a tool for prediction of bioavailability. Therefore, enhancing dissolution of drugs is of foremost concern for Pharma industry. Current trends in dissolution enhancement technologies detail about use of more sophisticated instruments and techniques to generate nano particulate and microparticulate forms of active pharmaceutical ingredients.
6 views
Seen by:Lamoure J. How Do You Treat Internet Addiction. Cdn J of CME 2012; 24(3): 14
Lamoure J. How Do You Treat Internet Addiction. Cdn J of CME 2012; 24(3): 14
There are not many formats or forums at this point that address Internet addiction, and there is even some debate over... more
There are not many formats or forums at this point that address Internet addiction, and there is even some debate over whether internet addiction is a true addiction. In my clinical experience and given definitions of addiction, "I would place internet as
being a very highly addictive medium."........
...... It provides a strong “hook” to those who are looking for a form of escapism. That being said, it is legal, cost effective, accessible, and provides instant gratification. It can, however, have a deleterious impact on the patient’s quality and quantity of life, with psychosocial retardation, financial challenges, and relationship challenges.
Much like patients with food or shopping addictions, there is the challenge that it cannot be easily extricated from daily life, especially in western and first/second world countries. Standard strategies that include removal of the offending agent will not work with internet addictions as there is exposure in insidious ways.......
From "Lamoure J. How Do You Treat Internet Addiction. Cdn J of CME 2012; 24(3): 14" (In press)
Dr. Joel W. Lamoure RPh., DD., FASCP
http://www.joelwlamoure.com/id6.html
Lamoure J., Stovel J. Varenicline and Suicidal Ideations. How Common is It?. Cdn J of CME 2012; 24(2): 14
Lamoure J., Stovel J. Varenicline and Suicidal Ideations. How Common is It?. Cdn J of CME 2012; 24(2): 14
Dr Joel Lamoure
In Canada, varenicline is currently indicated for smoking cessation in conjunction with counselling.1 There have been... more In Canada, varenicline is currently indicated for smoking cessation in conjunction with counselling.1 There have been numerous reports of increased suicidal ideation in patients taking varenicline, and in patients that are quitting smok- ing. This has resulted in the Health Canada Advisory warning health- care providers about the increased risk of serious neuropsychiatric adverse events in those patients taking varenicline. Specifically, depressed mood, agitation, hostili- ty, changes in behaviour, suicidal ideation and suicide, as well as worsening of pre-existing psychi- atric illness have been observed.2 This scenario is very reminiscent for me of the mid 1980’s when fluoxe- tine was first launched in the USA.
22 views
Seen by:Medication safety in community pharmacy: a qualitative study of the sociotechnical context
Phipps, D.L., Noyce, P.R., Parker, D., & Ashcroft, D.M. (2009). Medication safety in community pharmacy: a qualitative study of the sociotechnical context. BMC Health Services Research, 9, 158.
Background
While much research has been conducted on medication safety, few of these studies have addressed... more
Background
While much research has been conducted on medication safety, few of these studies have addressed primary care, despite the high volume of prescribing and dispensing of medicines that occurs in this setting. Those studies that have examined primary care dispensing emphasised the need to understand the role of sociotechnical factors (that is, the interactions between people, tasks, equipment and organisational structures) in promoting or preventing medication incidents. The aim of this study was to identify sociotechnical factors that community pharmacy staff encounter in practice, and suggest how these factors might impact on medication safety.
Methods
Sixty-seven practitioners, working in the North West of England, took part in ten focus groups on risk management in community pharmacy. The data obtained from these groups was subjected to a qualitative analysis to identify recurrent themes pertaining to sociotechnical aspects of medication safety.
Results
The findings indicated several characteristics of participants' work settings that were potentially related to medication safety. These were broadly classified as relationships involving the pharmacist, demands on the pharmacist and management and governance of pharmacists.
Conclusion
It is recommended that the issues raised in this study be considered in future work examining medication safety in primary care.
The Collaborative Patient/Person-Centric Care Model (CPCCM) Introducing a new paradigm in patient care involving an evidence-informed approach. Canadian Healthcare Network. EPublished 7 March 2011. http://www.canadianhealthcarenetwork.ca/
Official Citation for references:
Lamoure J., Stovel J., Piamonte M., Benbow S., Singh P., Steenstra J., Singh P., Moore K, Burgess S. The Collaborative Patient/Person-Centric Care Model (CPCCM) Introducing a new paradigm in patient care involving an evidence-informed approach. Canadian Healthcare Network. EPublished 7 March 2011. http://www.canadianhealthcarenetwork.ca/
Contact: jlamour@uwo.ca
"Patient care has traditionally been guided by the conventional paradigm known as the medical or biomedical... more
"Patient care has traditionally been guided by the conventional paradigm known as the medical or biomedical model, whose roots can be traced back to the era of reductionism and mind-body dualism, which separates the mental from the somatic. (Engel, 1977) In this model, disease is defined as a biophysical malfunction. (Engel, 1977) In the biomedical model, the goal of treatment is to correct the malfunction in order to cure the disease. (Engel, 1977) As such, this traditional medical model places the pathophysiology of the disease, objective tests, and therapeutic interventions at the centre of patient care. (McCollum, 2009) Such a model offers a one-dimensional approach to patient care that excludes the patient experience of illness and how this might impact other facets of the patient’s life (e.g., work disability, finances, social networks, etc.) because they are believed to lie outside of medicine’s responsibility and authority. (McCollum, 2009; Engel, 1977)
By incorporating other psychological (e.g., thoughts, emotions, behaviors) and social dimensions of the patient into the care plan, one moves towards the bio-psycho-social (BPS) model of patient care. (Phelps, 2009) The BPS model was first theorized by a psychiatrist, Dr. George L. Engel, in 1977. (Engel, 1977) In the BPS model, patient care is based on the belief that psychological and social dimensions also contribute significantly to human functioning within the context of disease or illness and, as such, need to be considered when providing care to a patient. (Engel, 1977) Specifically, the biological component examines the cause of the illness and how it affects the functioning of the body. (Engel, 1977) The psychological component of the model explores any potential psychological causes for the illness (e.g., lack of self-control, emotional stressors, negative-thinking, etc.). (Engel, 1977) Finally, the social component considers how different social factors (e.g., socioeconomic status, religion, culture, etc.) impact illness. (Engel, 1977) In order to address all aspects of this three-dimensional model, an integrated team approach involving allied healthcare professionals such as physicians, nurses, psychologists, pharmacists, social workers, and rehabilitation specialists are critical for ensuring that more comprehensive patient care is provided. (Phelps, 2009) Overall, the underlying premise of the BPS model is that the body and mind are intricately connected and what affects one will affect the other. (Halligan, 2006; Freudenreich, 2010) However, while this model advances patient care and can address the dis-ease that exists within the disease, it still does not encompass the patient as a “whole” and consider all the multitude of facets that make up the individual.
An alternative model to the biomedical and BPS model of care is the recovery model. In the recovery model, the patient is involved in a lifelong recovery process that involves a number of incremental steps across various facets of his or her life. (Turton, 2010) Moreover, the primary illness is seen as only one dimension in the patient’s recovery process. (Turton, 2010) Other key aspects of this model include negotiating treatment approaches between patients and practitioners such that the patient feels empowered. (Turton, 2010) Moreover, this model enables patients to regain their dignity and identity beyond the illness. (Turton, 2010) As such, this model takes the BPS model and advances it forward to include other patient dimensions in the provision of their care. Thus, the underlying ethos of this model for the patient is one of hope and optimism. (Turton, 2010)
A recent study conducted in ten European countries aimed to examine the recovery model of patient care in order to identify aspects of care that key stakeholders believed to be most important in the promoting recovery, specifically in patients with mental illness. (Turton, 2010) Eleven important domains of care identified by stakeholders in this study included: (1) social policy and human rights, (2) social inclusion, (3) self-management and autonomy, (4) therapeutic interventions, (5) governance, (6) staffing, (7) staff attitudes, (8) institutional environment, (9) post-discharge care, (10) caregivers, and (11) physical health care. (Turton, 2010) The authors also found that there was generally a high consensus between groups and countries with some modest differences in priorities noted. (Turton, 2010) Interesting, the most highly rated aspect of care was therapeutic interventions, a central piece of the more traditional medical model of care. (Turton, 2010) The authors suggest that stakeholders may still hold therapeutic interventions as the most important aspect of care because such interventions form the foundation and ‘raison d’être’ of health care. (Turton, 2010) Thus, it may be difficult for practitioners to step away from convention and embrace a new paradigm.
Incorporating various aspects of the BPS and recovery model of patient care, a patient-centered care (PCC) model has evolved over the last several years to replace the conventional biomedical model of care. (Laird-Fick, 2010) The Institute of Medicine (IOM) has stated that embracing a PCC model will help to close the “quality chasm” often present in the care provided to patients. (IOM, 2001) In a PCC model, the patient’s individuality is central. (Wolf, 2008) The patient has the right to have his or her needs, desires, beliefs, values, and goals respected and placed at the centre of the care plan. (Laird-Fick, 2010; Wolf, 2008) Such respect of the patient’s individuality is part of the team’s commitment to understand the patient’s perspective of his or her own health status and subsequent care. (Wolf, 2008) The underlying ethos of this model of care is that the patient has the right to respect, dignity, and care that focuses on the person and situation versus the disease process. (Wolf, 2008)
Our hypothesis is that the medical and bio-psycho-social models act as an essential foundation on which a more patient functionality centered model evolves: the Collaborative Patient/Person-Centric Care Model (CPCCM). This has a paradigm shift in the deliverables of patient care which involves talking to patients and family, listening to their desired outcomes, collaborating with allied health team members in order to help facilitate these patient goals, and finally formulating an individualized care plan that combines the patient’s wishes with the clinical endpoints derived from a uniform therapeutic thought process. The root of this theory is enmeshed in goal driven outcomes, as are the other models. However the goal is driven by the patient and then filtered through the professional lenses of the members of the treating team versus the converse. This evidence-informed versus evidence-based approach is more patient centric than when outcomes are determined independently by clinicians in a traditional hierarchical structure. This also allows the current structure to be realigned along a linear axis. (Lamoure 2008)" Joel Lamoure, Jessica Stovel, Matthew Piamonte et al.
560 views
Seen by: and 13 moreLamoure J. Collaborative Patient Centered Care Model (CPCCM): Applicability to Bioequivalence.- (Oral Presentation and Abstract)
Lamoure J. Collaborative Patient Centered Care Model (CPCCM): Applicability to Bioequivalence. (Oral Presentation and... more Lamoure J. Collaborative Patient Centered Care Model (CPCCM): Applicability to Bioequivalence. (Oral Presentation and Abstract). Presented at Canadian Pharmacists Association 99th Annual Conference Montreal, Quebec, Canada. May 30,2011
94 views
Seen by: and 3 moreRationale of Combining More than One Antipsychotic in a LTC/Nursing Home Patient at Same Time
Lamoure J. Rationale of Combining More than One Antipsychotic in a LTC/Nursing Home Patient at Same Time .... more Lamoure J. Rationale of Combining More than One Antipsychotic in a LTC/Nursing Home Patient at Same Time . Canadian Healthcare Network ATE Panel. October, 2011. http://www.canadianhealthcarenetwork.ca/pharmacists/discussions/the-experts/mental-health
Forecasting the Cost of Pharmaceutical Services for the City of Austin Medical Assistance Program
by Texas State PA Applied Research Projects
Lara, Jose D. , "Forecasting the Cost of Pharmaceutical Services for the City of Austin Medical Assistance Program" (1995). Applied Research Projects, Texas State University-San Marcos. Paper 133.
http://ecommons.txstate.edu/arp/133
Introducing the Scorecard to Pharmacy Benefit Manager
by Texas State PA Applied Research Projects
Pham, Kim, "Introducing the Scorecard to Pharmacy Benefit Manager" (2004). Applied Research Projects, Texas State University-San Marcos. Paper 20.
http://ecommons.txstate.edu/arp/20
Prescription drugs are considered the fasting growing component of national health care expenditures, experiencing... more
Prescription drugs are considered the fasting growing component of national health care expenditures, experiencing double-digit growth rates in the last 6 years. The rising cost of prescription drugs has gained the attention of policy makers, health plan sponsors, health care practitioners, and patients. Many have looked to pharmacy benefit management companies to help achieve cost effective, high quality pharmaceutical care at a high level of service.
The pharmacy benefit management industry has performance measures that help track progress towards this goal. This study identified performance measures employed in the pharmacy benefit management industry. The measures are classified using the Balanced Scorecard model. This management tool enables the industry to more fully use performance measures. Using the Balanced Scorecard framework, a survey was developed to determine the extent of use of the identified performance measures. The survey was sent to mid to senior managers of pharmacy benefit management companies.
The findings revealed financial related measures were most commonly used. The second most commonly used measures were those relating to internal business processes followed by learning and growth measures. The least most commonly used measures were those relating to customers.
Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction
by Frances Mair
This was a late breaking trial at the American Heart Association Mtg on 14 November 2011. It is the largest and longest study of a pharmacist intervention for heart failure published to date. Co-authored with: Richard Lowrie, Nicola Greenlaw, Paul Forsyth, Pardeep S. Jhund, Alex McConnachie, Brian Rae and John J.V. McMurray.
Background Meta-analysis of small trials suggests that pharmacist-led collaborative review and revision of... more
Background Meta-analysis of small trials suggests that pharmacist-led collaborative review and revision of medical treatment may improve outcomes in heart failure.
Methods and results We studied patients with left ventricular systolic dysfunction in a cluster-randomized controlled, event driven, trial in primary care. We allocated 87 practices (1090 patients) to pharmacist intervention and 87 practices (1074 patients) to usual care. The intervention was delivered by non-specialist pharmacists working with family doctors to optimize medical treatment. The primary outcome was a composite of death or hospital admission for worsening heart failure. This trial is registered, number ISRCTN70118765. The median follow-up was 4.7 years. At baseline, 86% of patients in both groups were treated with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. In patients not receiving one or other of these medications, or receiving less than the recommended dose, treatment was started, or the dose increased, in 33.1% of patients in the intervention group and in 18.5% of the usual care group [odds ratio (OR) 2.26, 95% CI 1.64–3.10; P< 0.001]. At baseline, 62% of each group were treated with a β-blocker and the proportions starting or having an increase in the dose were 17.9% in the intervention group and 11.1% in the usual care group (OR 1.76, 95% CI 1.31–2.35; P< 0.001). The primary outcome occurred in 35.8% of patients in the intervention group and 35.4% in the usual care group (hazard ratio 0.97, 95% CI 0.83–1.14; P = 0.72). There was no difference in any secondary outcome.
Conclusion A low-intensity, pharmacist-led collaborative intervention in primary care resulted in modest improvements in prescribing of disease-modifying medications but did not improve clinical outcomes in a population that was relatively well treated at baseline.

